NZ599556A - Combination therapy with a compound acting as a platelet adp receptor inhibitor - Google Patents
Combination therapy with a compound acting as a platelet adp receptor inhibitorInfo
- Publication number
- NZ599556A NZ599556A NZ599556A NZ59955608A NZ599556A NZ 599556 A NZ599556 A NZ 599556A NZ 599556 A NZ599556 A NZ 599556A NZ 59955608 A NZ59955608 A NZ 59955608A NZ 599556 A NZ599556 A NZ 599556A
- Authority
- NZ
- New Zealand
- Prior art keywords
- inhibitor
- medicament
- methyl
- therapeutic agent
- thrombotic
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 102000007466 Purinergic P2 Receptors Human genes 0.000 title 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 4
- DIEPFYNZGUUVHD-UHFFFAOYSA-N 2-[(4-chlorophenyl)methyl]-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid Chemical compound N=1C2=C3CCCCC3=CC=C2C(C(=O)O)=C(O)C=1CC1=CC=C(Cl)C=C1 DIEPFYNZGUUVHD-UHFFFAOYSA-N 0.000 abstract 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 abstract 2
- 238000001356 surgical procedure Methods 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 230000001732 thrombotic effect Effects 0.000 abstract 2
- WUPZRLYEGIXBNO-UHFFFAOYSA-N 1-(5-chlorothiophen-2-yl)sulfonyl-1-[4-[6-fluoro-7-(methylamino)-2,4-dioxo-1h-quinazolin-3-yl]phenyl]urea Chemical compound O=C1C=2C=C(F)C(NC)=CC=2NC(=O)N1C(C=C1)=CC=C1N(C(N)=O)S(=O)(=O)C1=CC=C(Cl)S1 WUPZRLYEGIXBNO-UHFFFAOYSA-N 0.000 abstract 1
- 206010002388 Angina unstable Diseases 0.000 abstract 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- 206010051055 Deep vein thrombosis Diseases 0.000 abstract 1
- JYGLAHSAISAEAL-UHFFFAOYSA-N Diphenadione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 JYGLAHSAISAEAL-UHFFFAOYSA-N 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- 108010071241 Factor XIIa Proteins 0.000 abstract 1
- 101001024703 Homo sapiens Nck-associated protein 5 Proteins 0.000 abstract 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 abstract 1
- 102100036946 Nck-associated protein 5 Human genes 0.000 abstract 1
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 abstract 1
- 101710137390 P-selectin glycoprotein ligand 1 Proteins 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 206010037549 Purpura Diseases 0.000 abstract 1
- 241001672981 Purpura Species 0.000 abstract 1
- LDXDSHIEDAPSSA-OAHLLOKOSA-N Ramatroban Chemical compound N([C@@H]1CCC=2N(C3=CC=CC=C3C=2C1)CCC(=O)O)S(=O)(=O)C1=CC=C(F)C=C1 LDXDSHIEDAPSSA-OAHLLOKOSA-N 0.000 abstract 1
- 208000007718 Stable Angina Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 108090000190 Thrombin Proteins 0.000 abstract 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 abstract 1
- 208000032109 Transient ischaemic attack Diseases 0.000 abstract 1
- 208000007814 Unstable Angina Diseases 0.000 abstract 1
- 206010047249 Venous thrombosis Diseases 0.000 abstract 1
- 229960002054 acenocoumarol Drugs 0.000 abstract 1
- VABCILAOYCMVPS-UHFFFAOYSA-N acenocoumarol Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=C([N+]([O-])=O)C=C1 VABCILAOYCMVPS-UHFFFAOYSA-N 0.000 abstract 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 1
- 238000002399 angioplasty Methods 0.000 abstract 1
- 239000002876 beta blocker Substances 0.000 abstract 1
- 229940097320 beta blocking agent Drugs 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 238000013172 carotid endarterectomy Methods 0.000 abstract 1
- 229960001307 clorindione Drugs 0.000 abstract 1
- NJDUWAXIURWWLN-UHFFFAOYSA-N clorindione Chemical compound C1=CC(Cl)=CC=C1C1C(=O)C2=CC=CC=C2C1=O NJDUWAXIURWWLN-UHFFFAOYSA-N 0.000 abstract 1
- 229960001259 diclofenac Drugs 0.000 abstract 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 abstract 1
- 229960001912 dicoumarol Drugs 0.000 abstract 1
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 abstract 1
- HIZKPJUTKKJDGA-UHFFFAOYSA-N dicumarol Natural products O=C1OC2=CC=CC=C2C(=O)C1CC1C(=O)C2=CC=CC=C2OC1=O HIZKPJUTKKJDGA-UHFFFAOYSA-N 0.000 abstract 1
- 229960000267 diphenadione Drugs 0.000 abstract 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 abstract 1
- OEHFRZLKGRKFAS-UHFFFAOYSA-N droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 abstract 1
- 229960001850 droxicam Drugs 0.000 abstract 1
- 229960002822 ethyl biscoumacetate Drugs 0.000 abstract 1
- SEGSDVUVOWIWFX-UHFFFAOYSA-N ethyl biscoumacetate Chemical compound C1=CC=C2C(=O)C(C(C=3C(C4=CC=CC=C4OC=3O)=O)C(=O)OCC)=C(O)OC2=C1 SEGSDVUVOWIWFX-UHFFFAOYSA-N 0.000 abstract 1
- 229940087051 fragmin Drugs 0.000 abstract 1
- 229960001680 ibuprofen Drugs 0.000 abstract 1
- 229960000905 indomethacin Drugs 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 abstract 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 abstract 1
- 239000003055 low molecular weight heparin Substances 0.000 abstract 1
- 229940127215 low-molecular weight heparin Drugs 0.000 abstract 1
- 229940103185 mefenamate Drugs 0.000 abstract 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960002009 naproxen Drugs 0.000 abstract 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 abstract 1
- 229960000280 phenindione Drugs 0.000 abstract 1
- NFBAXHOPROOJAW-UHFFFAOYSA-N phenindione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C1=CC=CC=C1 NFBAXHOPROOJAW-UHFFFAOYSA-N 0.000 abstract 1
- 229960004923 phenprocoumon Drugs 0.000 abstract 1
- DQDAYGNAKTZFIW-UHFFFAOYSA-N phenprocoumon Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC)C1=CC=CC=C1 DQDAYGNAKTZFIW-UHFFFAOYSA-N 0.000 abstract 1
- 229960002702 piroxicam Drugs 0.000 abstract 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 abstract 1
- 201000011461 pre-eclampsia Diseases 0.000 abstract 1
- 229950004496 ramatroban Drugs 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960003329 sulfinpyrazone Drugs 0.000 abstract 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 abstract 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 abstract 1
- 229960000894 sulindac Drugs 0.000 abstract 1
- XUTLOCQNGLJNSA-RGVLZGJSSA-N terbogrel Chemical compound CC(C)(C)\N=C(/NC#N)NC1=CC=CC(C(=C/CCCC(O)=O)\C=2C=NC=CC=2)=C1 XUTLOCQNGLJNSA-RGVLZGJSSA-N 0.000 abstract 1
- 229950006665 terbogrel Drugs 0.000 abstract 1
- HWEOXFSBSQIWSY-UHFFFAOYSA-N terutroban Chemical compound C1CC2=C(CCC(O)=O)C(C)=CC=C2CC1NS(=O)(=O)C1=CC=C(Cl)C=C1 HWEOXFSBSQIWSY-UHFFFAOYSA-N 0.000 abstract 1
- 229960004072 thrombin Drugs 0.000 abstract 1
- 229960001060 tioclomarol Drugs 0.000 abstract 1
- WRGOVNKNTPWHLZ-UHFFFAOYSA-N tioclomarol Chemical compound C=1C=C(Cl)C=CC=1C(O)CC(C=1C(OC2=CC=CC=C2C=1O)=O)C1=CC=C(Cl)S1 WRGOVNKNTPWHLZ-UHFFFAOYSA-N 0.000 abstract 1
- 201000010875 transient cerebral ischemia Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- ZBGXUVOIWDMMJE-QHNZEKIYSA-N vorapaxar Chemical compound C(/[C@@H]1[C@H]2[C@H](C(O[C@@H]2C)=O)C[C@H]2[C@H]1CC[C@H](C2)NC(=O)OCC)=C\C(N=C1)=CC=C1C1=CC=CC(F)=C1 ZBGXUVOIWDMMJE-QHNZEKIYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91564907P | 2007-05-02 | 2007-05-02 | |
| US91591107P | 2007-05-03 | 2007-05-03 | |
| US94792107P | 2007-07-03 | 2007-07-03 | |
| US97870007P | 2007-10-09 | 2007-10-09 | |
| NZ581324A NZ581324A (en) | 2007-05-02 | 2008-05-02 | Combination therapy with a compound acting as a platelet adp receptor inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ599556A true NZ599556A (en) | 2013-10-25 |
Family
ID=39587017
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ599556A NZ599556A (en) | 2007-05-02 | 2008-05-02 | Combination therapy with a compound acting as a platelet adp receptor inhibitor |
| NZ581324A NZ581324A (en) | 2007-05-02 | 2008-05-02 | Combination therapy with a compound acting as a platelet adp receptor inhibitor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ581324A NZ581324A (en) | 2007-05-02 | 2008-05-02 | Combination therapy with a compound acting as a platelet adp receptor inhibitor |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20080279845A1 (https=) |
| EP (2) | EP2146705B1 (https=) |
| JP (1) | JP5439363B2 (https=) |
| KR (1) | KR101509829B1 (https=) |
| CN (1) | CN101686959B (https=) |
| AU (1) | AU2008247435A1 (https=) |
| BR (1) | BRPI0811000A2 (https=) |
| CA (1) | CA2684722A1 (https=) |
| CO (1) | CO6241105A2 (https=) |
| EA (1) | EA020045B1 (https=) |
| EC (1) | ECSP099775A (https=) |
| ES (1) | ES2467468T3 (https=) |
| GT (1) | GT200900283A (https=) |
| IL (1) | IL201826A (https=) |
| MA (1) | MA31396B1 (https=) |
| MX (1) | MX2009011755A (https=) |
| NZ (2) | NZ599556A (https=) |
| PT (1) | PT2146705E (https=) |
| TN (1) | TN2009000444A1 (https=) |
| WO (1) | WO2008137787A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001250783A1 (en) * | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| KR101195801B1 (ko) * | 2004-06-18 | 2012-11-05 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ｘａ 인자 억제제 |
| US7696352B2 (en) * | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
| CN102775396B (zh) | 2005-11-08 | 2014-10-08 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的杂环调控剂 |
| WO2007112367A2 (en) * | 2006-03-27 | 2007-10-04 | Portola Pharmaceuticals, Inc. | Potassium channel modulators and platelet procoagulant activity |
| MX2008014193A (es) * | 2006-05-05 | 2009-03-31 | Millennium Pharm Inc | Inhibidores del factor xa. |
| ES2550057T3 (es) | 2006-11-02 | 2015-11-04 | Millennium Pharmaceuticals, Inc. | Métodos para sintetizar sales farmacéuticas de un inhibidor del Factor Xa |
| JP2010515691A (ja) * | 2007-01-05 | 2010-05-13 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 第Ｘａ因子阻害剤 |
| EP2155195B1 (en) * | 2007-04-13 | 2014-07-16 | Millennium Pharmaceuticals, Inc. | Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor |
| EP3683218B1 (en) | 2007-12-07 | 2024-09-18 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
| EP2376065A2 (en) * | 2008-11-14 | 2011-10-19 | Portola Pharmaceuticals, Inc. | Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof |
| CA2784921A1 (en) | 2009-12-17 | 2011-07-14 | Millennium Pharmaceuticals, Inc. | Salts and crystalline forms of a factor xa inhibitor |
| US8742120B2 (en) | 2009-12-17 | 2014-06-03 | Millennium Pharmaceuticals, Inc. | Methods of preparing factor xa inhibitors and salts thereof |
| US8663661B2 (en) * | 2009-12-23 | 2014-03-04 | Ratiopharm Gmbh | Solid pharmaceutical dosage form of ticagrelor |
| WO2011089168A2 (fr) * | 2010-01-21 | 2011-07-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Composition particuliere pour son application comme medicament |
| IN2012DN06587A (https=) * | 2010-02-25 | 2015-10-23 | Bristol Myers Squibb Co | |
| JP2013523833A (ja) | 2010-04-07 | 2013-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与 |
| TW201221128A (en) * | 2010-09-01 | 2012-06-01 | Portola Pharm Inc | Crystalline forms of a factor Xa inhibitor |
| ES2539236T3 (es) * | 2011-03-29 | 2015-06-29 | Sanofi | Sal de ácido benzoico de Otamixaban |
| WO2013033370A1 (en) * | 2011-08-31 | 2013-03-07 | Portola Pharmaceuticals, Inc. | Prevention and treatment of thrombosis in medically ill patients |
| NZ727015A (en) | 2012-01-25 | 2017-12-22 | Vertex Pharma | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| US9695198B2 (en) | 2012-12-19 | 2017-07-04 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| EP2934537B1 (en) * | 2012-12-19 | 2018-04-04 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
| US9708308B2 (en) | 2012-12-19 | 2017-07-18 | Merck Sharp Dohme Corp. | Factor IXa inhibitors |
| US9200268B2 (en) | 2012-12-27 | 2015-12-01 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
| AU2014349010C1 (en) | 2013-11-12 | 2020-08-06 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases |
| US9676723B2 (en) * | 2014-02-11 | 2017-06-13 | Merck Sharp & Dohme Corp | Factor XIa inhibitors |
| CN106831553A (zh) * | 2015-09-11 | 2017-06-13 | 天津科伦药物研究有限公司 | 贝曲西班或其类似物的制备方法 |
| CN105250286A (zh) * | 2015-11-13 | 2016-01-20 | 谭惠娟 | 一种抗血栓组合物 |
| EP3254674A1 (en) * | 2016-06-08 | 2017-12-13 | Sandoz Ag | Pharmaceutical compositions of betrixaban maleate |
| WO2018093695A1 (en) | 2016-11-18 | 2018-05-24 | Merck Sharp & Dohme Corp. | FACTOR XIIa INHIBITORS |
| US11654036B2 (en) | 2020-05-26 | 2023-05-23 | Elixir Medical Corporation | Anticoagulant compounds and methods and devices for their use |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6440147B1 (en) * | 1998-09-03 | 2002-08-27 | Rubicor Medical, Inc. | Excisional biopsy devices and methods |
| US6509348B1 (en) * | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
| EP1156803A4 (en) * | 1999-02-09 | 2004-03-17 | Bristol Myers Squibb Co | FXA LACTAM INHIBITORS AND METHOD |
| DE60040676D1 (de) | 1999-09-17 | 2008-12-11 | Millennium Pharm Inc | BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa |
| US6844367B1 (en) * | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| US6906063B2 (en) * | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| AU2001250783A1 (en) * | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| US7235567B2 (en) | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| US20040192753A1 (en) | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
| US7312325B2 (en) | 2000-09-26 | 2007-12-25 | Duke University | RNA aptamers and methods for identifying the same |
| US7312235B2 (en) * | 2001-03-30 | 2007-12-25 | Millennium Pharmaceuticals, Inc. | Benzamide inhibitors of factor Xa |
| CN1780823A (zh) * | 2003-04-09 | 2006-05-31 | 日本烟草产业株式会社 | 杂芳族五环化合物及其医药应用 |
| JP4879745B2 (ja) * | 2003-10-03 | 2012-02-22 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 置換イソキノリノン |
| DE602004024910D1 (de) * | 2003-10-09 | 2010-02-11 | Millennium Pharm Inc | Thioethersubstituierte benzamide als inhibitoren von faktor xa |
| US7696352B2 (en) * | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
| KR101195801B1 (ko) * | 2004-06-18 | 2012-11-05 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ｘａ 인자 억제제 |
| WO2006045756A1 (en) * | 2004-10-25 | 2006-05-04 | Boehringer Ingelheim International Gmbh | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases |
| JP2008528691A (ja) | 2005-02-02 | 2008-07-31 | ビテ ファーマシューティカルズ， インコーポレイテッド | レニン阻害剤としての１−アシルアミノ−２−ヒドロキシ−３−アミノ−ω−アリールアルカン |
| US7467697B2 (en) * | 2005-10-07 | 2008-12-23 | Ford Global Technologies, Llc | Electromagnetic coupling device for engine accessories |
| KR101423483B1 (ko) | 2005-11-03 | 2014-07-28 | 포톨라 파마슈티컬스, 인코포레이티드 | 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법 |
| NZ592533A (en) | 2005-11-08 | 2012-08-31 | Millennium Pharm Inc | METHOD FOR THE PREPARATION OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO]-5-METHOXY-BENZAMIDE, A FACTOR Xa INHIBITOR |
| WO2007112367A2 (en) * | 2006-03-27 | 2007-10-04 | Portola Pharmaceuticals, Inc. | Potassium channel modulators and platelet procoagulant activity |
| MX2008014193A (es) | 2006-05-05 | 2009-03-31 | Millennium Pharm Inc | Inhibidores del factor xa. |
| CN105193799A (zh) * | 2006-12-08 | 2015-12-30 | 米伦纽姆医药公司 | 使用经口因子xa抑制剂治疗血栓形成的单位剂量调配物和方法 |
| JP2010515691A (ja) * | 2007-01-05 | 2010-05-13 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 第Ｘａ因子阻害剤 |
| EP2155195B1 (en) * | 2007-04-13 | 2014-07-16 | Millennium Pharmaceuticals, Inc. | Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor |
-
2008
- 2008-05-02 MX MX2009011755A patent/MX2009011755A/es active IP Right Grant
- 2008-05-02 CA CA002684722A patent/CA2684722A1/en not_active Abandoned
- 2008-05-02 KR KR1020097024870A patent/KR101509829B1/ko not_active Expired - Fee Related
- 2008-05-02 WO PCT/US2008/062561 patent/WO2008137787A2/en not_active Ceased
- 2008-05-02 EA EA200901442A patent/EA020045B1/ru not_active IP Right Cessation
- 2008-05-02 US US12/114,706 patent/US20080279845A1/en not_active Abandoned
- 2008-05-02 JP JP2010506696A patent/JP5439363B2/ja not_active Expired - Fee Related
- 2008-05-02 AU AU2008247435A patent/AU2008247435A1/en not_active Abandoned
- 2008-05-02 EP EP08747590.1A patent/EP2146705B1/en not_active Not-in-force
- 2008-05-02 NZ NZ599556A patent/NZ599556A/xx not_active IP Right Cessation
- 2008-05-02 PT PT87475901T patent/PT2146705E/pt unknown
- 2008-05-02 ES ES08747590.1T patent/ES2467468T3/es active Active
- 2008-05-02 NZ NZ581324A patent/NZ581324A/en not_active IP Right Cessation
- 2008-05-02 BR BRPI0811000-0A2A patent/BRPI0811000A2/pt not_active Application Discontinuation
- 2008-05-02 EP EP13151486.1A patent/EP2586439A1/en not_active Withdrawn
- 2008-05-02 CN CN200880021658.3A patent/CN101686959B/zh not_active Expired - Fee Related
-
2009
- 2009-10-23 TN TNP2009000444A patent/TN2009000444A1/fr unknown
- 2009-10-29 IL IL201826A patent/IL201826A/en not_active IP Right Cessation
- 2009-10-30 GT GT200900283A patent/GT200900283A/es unknown
- 2009-11-20 CO CO09132196A patent/CO6241105A2/es not_active Application Discontinuation
- 2009-11-26 MA MA32375A patent/MA31396B1/fr unknown
- 2009-12-01 EC EC2009009775A patent/ECSP099775A/es unknown
-
2010
- 2010-10-20 US US12/908,837 patent/US8946219B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20110033459A1 (en) | 2011-02-10 |
| ECSP099775A (es) | 2010-01-29 |
| ES2467468T3 (es) | 2014-06-12 |
| HK1138765A1 (en) | 2010-09-03 |
| IL201826A (en) | 2014-08-31 |
| KR101509829B1 (ko) | 2015-04-06 |
| MA31396B1 (fr) | 2010-05-03 |
| KR20100023836A (ko) | 2010-03-04 |
| CA2684722A1 (en) | 2008-11-13 |
| JP2010526103A (ja) | 2010-07-29 |
| EP2146705B1 (en) | 2014-03-05 |
| CN101686959A (zh) | 2010-03-31 |
| EP2146705A2 (en) | 2010-01-27 |
| WO2008137787A2 (en) | 2008-11-13 |
| IL201826A0 (en) | 2010-06-16 |
| EA200901442A1 (ru) | 2010-06-30 |
| TN2009000444A1 (en) | 2011-03-31 |
| EA020045B1 (ru) | 2014-08-29 |
| EP2586439A1 (en) | 2013-05-01 |
| AU2008247435A1 (en) | 2008-11-13 |
| CO6241105A2 (es) | 2011-01-20 |
| MX2009011755A (es) | 2010-02-12 |
| US20080279845A1 (en) | 2008-11-13 |
| PT2146705E (pt) | 2014-05-23 |
| NZ581324A (en) | 2012-05-25 |
| WO2008137787A3 (en) | 2009-02-05 |
| BRPI0811000A2 (pt) | 2015-01-27 |
| US8946219B2 (en) | 2015-02-03 |
| CN101686959B (zh) | 2014-05-07 |
| GT200900283A (es) | 2011-10-05 |
| JP5439363B2 (ja) | 2014-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ599556A (en) | Combination therapy with a compound acting as a platelet adp receptor inhibitor | |
| Broussalis et al. | Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention | |
| Harder et al. | Novel oral anticoagulants: clinical pharmacology, indications and practical considerations | |
| Patrono et al. | Platelet-active drugs: the relationships among dose, effectiveness, and side effects | |
| Bauer et al. | Targeting PI3 kinase in cancer | |
| KR101473207B1 (ko) | Ｘａ 인자 억제제로서 작용하는 화합물과의 병용 항응고 요법 | |
| Levi et al. | Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management | |
| Costopoulos et al. | Novel oral anticoagulants in acute coronary syndrome | |
| KR20160104612A (ko) | 비산트렌의 치료 효과 개선용 조성물 | |
| US20050014770A1 (en) | Use of dipyridamole or mopidamole for treatment and prevention of thromboembolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors | |
| Tsoumani et al. | Antiplatelet agents and anticoagulants: from pharmacology to clinical practice | |
| Goel et al. | Newer oral anticoagulant agents: a new era in medicine | |
| RU2014127884A (ru) | Способы лечения сердечно-сосудистого нарушения | |
| Schwenk et al. | Aldosterone blockade in CKD: emphasis on pharmacology | |
| CN103079554A (zh) | 在接受抗凝血剂疗法的哺乳动物中治疗高血压和/或预防或治疗心力衰竭 | |
| Sherman | Tyrosine kinase inhibitors and the thyroid | |
| EA029341B1 (ru) | Способы предоставления антитромбоцитарной терапии | |
| Kei et al. | Antiplatelet drugs: what comes next? | |
| Jacomella et al. | Novel anticoagulants in the therapy of peripheral arterial and coronary artery disease | |
| US20210196696A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor | |
| CN1747734A (zh) | 潘生丁或单哌潘生丁在治疗和预防mmp－9－依赖性疾病中的用途 | |
| Broussalis et al. | Latest developments in anticoagulant drug discovery | |
| Younis et al. | Antiplatelet drugs overview | |
| CA3139162C (en) | Methods for treating familial adenomatous polyposis | |
| Turpie | Oral Direct Factor Xa Inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |